Galapagos NV and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn’s disease. Galapagos will fund and complete a Phase II program in Crohn’s disease, and upon successful completion, AbbVie will pay Galapagos $50 million. AbbVie will be responsible for funding and performing clinical development beyond Phase II, as well as regulatory and commercialization activities.   “AbbVie supports the start of this innovative study in Crohn’s dise...